Search
Imetelstat
go.drugbank.com/drugs/DB14909ApprovedInvestigationalcell morphology and a risk for transformation to acute myeloid leukemia. … Imetelstat is a first-in-class 18-amino acid oligonucleotide that directly and competitively inhibits human telomerase.
Mavacamten
go.drugbank.com/drugs/DB14921ApprovedInvestigationalMavacamten is a myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM).
Synonyms: 6-(((1S)-1-Phenylethyl)amino)-3-(propan-2-yl)-1,2,3,4 tetrahydropyrimidine-2,4-dioneCategories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 SubstratesMotixafortide
go.drugbank.com/drugs/DB14939ApprovedInvestigational[L48136] Similar in mechanism to the previously approved [plerixafor], motixafortide is an inhibitor of C-X-C Motif Chemokine Receptor 4 (CXCR4), a protein that helps to anchor stem cells to bone marrow … Motixafortide is a cyclic peptide hematopoietic stem cell mobilizer used to improve stem cell collection prior to autologous transplantation.
Umbralisib
go.drugbank.com/drugs/DB14989ApprovedInvestigationalWithdrawnwith a possible increased risk of death outweighing the benefits. … Unfortunately, many patients experience a relapse or develop resistance to these drugs.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesBrepocitinib
go.drugbank.com/drugs/DB15003ApprovedInvestigationalBrepocitinib is an oral Janus kinase (JAK) and tyrosine kinase 2 (TYK2) inhibitor used to treat dermatomyositis in adults.
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsRogaratinib
go.drugbank.com/drugs/DB15078InvestigationalRogaratinib is under investigation in clinical trial NCT03762122 (Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC)).
Categories: Heterocyclic Compounds, 1-RingGefapixant
go.drugbank.com/drugs/DB15097ApprovedIt has been estimated that 5-10% of adults globally suffer from chronic cough, which is defined as a cough lasting longer than eight weeks. … [L48601] A subset of these patients remain symptomatic despite thorough investigation and treatment, termed refractory chronic cough (RCC) if they have a cough that does not respond to conventional treatment
Categories: MATE 1 Substrates, MATE 2 SubstratesRSV-604
go.drugbank.com/drugs/DB15197InvestigationalRSV-604 is under investigation in clinical trial NCT00416442 (Safety, Tolerability and Pharmacokinetic Study of Single and Multiple Intravenous Doses of RSV604 in Healthy Subjects.).
Categories: Heterocyclic Compounds, 2-RingAvutometinib
go.drugbank.com/drugs/DB15254ApprovedInvestigationalAvutometinib is a small molecule kinase inhibitor targeted against RAF/MEK1, key regulators of the RAS/RAF/MEK/ERK (MAPK) pathway. … [L53203,L53198] The MAPK pathway is implicated in variety of cancers, playing a key role in tumor cell proliferation, differentiation and survival.
Synonyms: N-(3-fluoro-4-((4-methyl-2-oxo-7-((pyrimidin-2-yl)oxy)-2H-1-benzopyran-3-yl)methyl)pyridin-2-yl)-N'-methylsulfuric diamide, Sulfamide, N-(3-fluoro-4-((4-methyl-2-oxo-7-(2-pyrimidinyloxy)-2H-1-benzopyran-3-yl)methyl)-2-pyridinyl)-N'-methyl-Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesAbivertinib
go.drugbank.com/drugs/DB15327Investigational[L17383] It has been investigated for use in the treatment of non-small cell lung cancer (NSCLC) and B-cell malignancies. … Abivertinib is a tyrosine kinase inhibitor targeted against mutant forms of both human epidermal growth factor receptor (EGFR) and Bruton's tyrosine kinase (BTK).
Categories: Heterocyclic Compounds, 1-Ring